Glucagon-like peptide-1 (GLP-1) is involved in a range of central and peripheral pathways
related to appetitive behavior. Hence, this study explored the effects of glucagon-like peptide …

The emergence of glucagon-like peptide-1 receptor agonists (GLP-1 RAs; semaglutide and
others) now promises effective, non-invasive treatment of obesity for individuals with and …

Cocaine use disorder (CUD) is a major public health challenge with a high relapse rate and
lack of effective pharmacotherapies; therefore, there is a substantial need to identify novel …

The role of glucagon-like peptide 1 (GLP-1) in insulin-dependent signaling is well-known;
GLP-1 enhances glucose-dependent insulin secretion and lowers blood glucose in …

Given that the search for effective pharmacotherapies for cocaine use disorder has, thus far,
been fruitless, there remains a critical need for conceptually innovative approaches toward …

Glucagon-like-peptide-1 (GLP-1) and its long acting analogs comprise a novel class of type
2 diabetes (T2D) treatment. What makes them unique among other T2D drugs is their …

Introduction The roles of metabolic signals, including Glucagon-like peptide 1 (GLP-1), have
been implicated in multiple domains outside metabolic regulation. There is a growing …

Highlights•GLP-1 receptor activation will influence multiple reward-related
behaviors.•Obesity and maladaptive reward behaviors can be treated by targeting reward …

Drug, alcohol and tobacco use disorders are a global burden affecting millions of people.
Despite decades of research, treatment options are sparse or missing, and relapse rates are …

Abstract Glucagon-like-peptide-1 (GLP-1)-receptor agonists have been proposed as
putative treatment for substance use disorders (SUD). The objective of this systematic review …